Recent Updates
Recently added Catalysts
SGHT Negative Sentiment Score: 30/100

Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Key Takeaway: Johnson Fistel, PLLP is investigating potential claims on behalf of Sight Sciences investors who have experienced losses. This comes after the company revealed its 2025 financial results and anticipated revenue for 2026, which led to a significant decline in stock price. The investigation aims to determine if the company adhered to federal securities laws, which could impact the ability of lost investors to recover their losses.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors of Sight Sciences may have suffered significant losses.
  • The company's stock price declined significantly following financial disclosures.
  • The investigation raises concerns about the company's compliance with federal securities laws.

Full Press Release Details

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Sight Sciences, Inc. (NASDAQ: SGHT). The investigation focuses on Sight Sciences executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased Sight Sciences securities?
If you purchased Sight Sciences securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
Background of the investigation
On March 4, 2026, Sight Sciences, Inc. reported its fourth quarter and full year 2025 financial results and initiated financial guidance for fiscal year 2026. Among other things, the Company projected total revenue of approximately $82 million to $88 million, including approximately $5 million to $7 million in Interventional Dry Eye revenue, which includes revenue associated with the Company’s TearCare platform.
Following these disclosures, Sight Sciences common stock declined significantly.
In light of this disclosure, Johnson Fistel is investigating whether Sight Sciences complied with the federal securities laws. If you suffered losses from your investment in Sight Sciences stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm’s effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs’ securities law firm in the United States, based on the total dollar value of final recoveries.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
James Baker, Investor Relations – or – Frank J. Johnson, Esq.

Tags

Frequently Asked Questions

What is Johnson Fistel investigating?

Johnson Fistel is investigating claims for investors of Sight Sciences, Inc., focusing on potential losses under federal securities laws.

How can I join the investigation?

If you've suffered losses from Sight Sciences securities, you can join the investigation by contacting Johnson Fistel.

What did Sight Sciences report on March 4, 2026?

Sight Sciences reported its Q4 and full year 2025 results, projecting revenues of $82 million to $88 million for 2026.

Has Sight Sciences' stock value declined recently?

Yes, Sight Sciences' stock declined significantly after announcing its financial guidance and results.

Who should I contact for more information?

For more details, you can reach out to Jim Baker at jimb@johnsonfistel.com or call (619) 814-4471.

Last updated: Mar 6, 2026